Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, other |
Gross |
Post- |
INITIAL OFFERINGS TOTAL: $687.65M | ||||||||
Chiasma Inc. (Newton, Mass.; CHMA)1 |
7/6/15 |
7/16/15 |
6.3S |
$16 |
22.975 |
Barclays (co-lead); Cowen and Co. (co-lead); William Blair; Oppenheimer & Co. |
$101.8 |
$367.6 |
Nantkwest Inc. (Cardiff-by-the-Sea, Calif.; NK)2 |
6/23/15 |
7/29/15 |
9.53S |
$25 |
80.17 |
BofA Merrill Lynch (co-lead); Citigroup (co-lead); Jefferies (co-lead); Piper Jaffray (co-lead); MLV & Co. |
$238.25 |
$2,004.25 |
Neos Therapeutics Inc. (Grand Prairie, Texas; NEOS)3 |
6/19/15 |
7/24/15 |
5.5S |
$15 |
15.13 |
UBS Investment Bank (co-lead); BMO Capital Markets (co-lead); RBC Capital Markets (co-lead); JMP Securities |
$72 |
$226.95 |
Pronai Therapeutics Inc. (Vancouver, British Columbia; DNAI)4 |
6/12/15 |
7/16/15 |
9.3S |
$17 |
30 |
Jefferies (co-lead); BofA Merrill Lynch (co-lead); Wedbush Pacgrow; Suntrust Robinson Humphrey |
$158.4 |
$510 |
Vtv Therapeutics Inc. (High Point, N.C.; VTVT)5 |
6/15/15 |
7/31/15 |
7.8S |
$15 |
7.812 |
Piper Jaffray (co-lead); Stifel, Nicolaus & Co. (co-lead); Canaccord Genuity; Janney Montgomery Scott |
$117.2 |
$117.18 |
|
Number of IPOs in July: 5 Average value of July IPOs: $137.53M Number of IPOs in 2015: 48 Total raised in IPOs in 2015: $4,707.03M Average value of IPOs in 2015: $98.06M | ||||||||
FOLLOW-ON OFFERINGS TOTAL: $2,598.35M | ||||||||
Acura Pharmaceuticals Inc. (ACUR) |
3/15/13 |
7/1/15 |
9.79S |
$0.78 |
59 |
Roth Capital Partners (lead) |
$7.64 |
$46.02 |
Amag Pharmaceuticals Inc. (Waltham, Mass.; AMAG)6 |
2/24/15 |
7/31/15 |
3.15S |
$63.75 |
34.02 |
Jefferies (co-lead); Barclays Capital (co-lead); Leerink Partners (co-lead); Guggenheim Securities; Raymond James |
$200.81 |
$2,168.78 |
Anthera Pharmaceuticals Inc. (Hayward, Calif.; ANTH)7 |
4/18/13 |
7/8/15 |
3.8S |
$7.50 |
44.15 |
Citigroup Global Markets (co-lead); Piper Jaffray (co-lead); Suntrust Robinson Humphrey |
$28.8 |
$331.13 |
Atara Biotherapeutics Inc. (San Francisco; ATRA)8 |
7/10/15 |
7/15/15 |
3.981S |
$52 |
28 |
Goldman, Sachs & Co. (co-lead); Citigroup Global Markets (co-lead); William Blair; Canaccord Genuity; JMP Securities |
$180 |
$1,446.74 |
Cara Therapeutics Inc. (Shelton, Conn.; CARA)9 |
5/13/15 |
7/30/15 |
3.76S |
$18.60 |
26.6 |
Stifel (co-lead); Piper Jaffray (co-lead); Canaccord Genuity Inc.; Needham & Co.; Janney Montgomery Scott |
$70 |
$494.76 |
Clovis Oncology Inc. (Boulder, Colo.; CLVS)10 |
7/11/13 |
7/9/15 |
3.53S |
$78 |
37.59 |
J.P. Morgan Securities; Credit Suisse Securities; Stifel; Mizuho Securities |
$275 |
$2,932.02 |
Cymabay Therapeutics Inc. (Newark, Calif.; CBAY)11 |
7/15/15 |
7/15/15 |
7.12S |
$2.81 |
22.369 |
Piper Jaffray (co-lead); Lifesci Capital (co-lead) |
$20 |
$62.86 |
Cytrx Corp. (Los Angeles; CYTR)12 |
12/23/13 |
7/22/15 |
10S |
$2.75 |
66.3 |
Jefferies (co-lead: Oppenheimer & Co. (co-lead); Aegis Capital (co-lead); FBR Capital Markets (co-lead); H.C. Wainwright & Co. (co-lead) |
$28.8 |
$182.33 |
DBV Technologies SA (Bagneux, France; Euronext Paris:DBV; DBVT)13 |
7/6/15 |
7/15/15 |
8.3ADS |
$34 |
23.58 |
Citigroup (co-lead); Morgan Stanley (co-lead); Barclays (co-lead); Leerink Partners (co-lead); H.C. Wainwright & Co. |
$244.8 |
$1,473.92 |
Discovery Laboratories Inc. (Warrington, Pa.; DSCO)14 |
6/13/14 |
7/21/15 |
16.33U |
$0.60 |
102.25 |
Stifel, Nicolaus & Co. (lead); H.C. Wainwright & Co.; LifeSci Capital |
$35 |
$61.35 |
Dynavax Technologies Corp. (Berkeley, Calif.; DVAX)15 |
12/3/14 |
7/22/15 |
5.2S |
$27.50 |
34.15 |
Cowen and Co. (co-lead); RBC Capital Markets (co-lead); William Blair (co-lead) |
$143 |
$939.13 |
Egalet Corp. (Wayne, Pa.; EGLT)16 |
5/6/15 |
7/28/15 |
7.6S |
$11.25 |
24.99 |
Stifel, Nicolaus & Co. (co-lead); Guggenheim Securities (co-lead) |
$86.3 |
$281.14 |
Exelixis Inc. (South San Francisco; EXEL)17 |
7/1/15 |
7/24/15 |
25S |
$5.40 |
221.02 |
Cowen and Co. (co-lead); William Blair (co-lead); Stifel (co-lead) |
$135 |
$1,193.51 |
Eyegate Pharmaceuticals Inc. (Waltham, Mass.; EYEG)18 |
7/31/15 |
7/31/15 |
1.2S and 1.2W |
$8.50 |
7.58 |
Aegis Capital (co-lead); Chardan Capital Markets (co-lead) |
$10 |
$64.43 |
Fibrocell Science Inc. (Exton, Pa.; FCSC)19 |
8/28/13 |
7/22/15 |
2.586S |
$5.80 |
43.5 |
Wells Fargo Securities (lead); Roth Capital Partners; Griffin Securities |
$15 |
$252.3 |
Genocea Biosciences Inc. (Cambridge, Mass.; GNCA)20 |
5/14/15 |
7/30/15 |
3.85S |
$13 |
27.99 |
Cowen and Co. (co-lead); Piper Jaffray (co-lead); Stifel, Nicolaus & Co. (co-lead); Needham & Co. |
$50.05 |
$363.87 |
Macrogenics Inc. (Rockville, Md.; MGNX)21 |
11/21/14 |
7/15/15 |
3.525S |
$37 |
33.648 |
Morgan Stanley (co-lead); Citigroup (co-lead); Leerink Partners (co-lead); Stifel; Wedbush Pacgrow; Roth Capital Partners |
$130.43 |
$1,244.98 |
Nephrogenex Inc. (Raleigh, N.C.; NRX)22 |
7/17/15 |
7/17/15 |
1.5U |
$6.25 |
10.36 |
Aegis Capital (lead) |
$9.38 |
$64.75 |
Neuroderm Ltd. (Rehovot, Israel; NDRM)23 |
7/17/15 |
7/17/15 |
4.5S |
$17.00 |
21.52 |
Jefferies (co-lead); Cowen and Co. (co-lead); Raymond James & Associates; Roth Capital Partners |
$77 |
$365.84 |
Radius Health Inc. (Waltham, Mass.; RDUS)24 |
1/20/15 |
7/23/15 |
4.7S |
$74.00 |
42.55 |
J.P. Morgan (co-lead); BofA Merrill Lynch (co-lead); Deutsche Bank Securities (co-lead); Cowen and Co. |
$347.8 |
$3,148.7 |
Redhill Biopharma Ltd. (Tel Aviv, Israel; RDHL)25 |
2/4/14 |
7/17/15 |
2.462ADS |
$16.25 |
124.22 |
Nomura (co-lead); Roth Capital Partners (co-lead); MLV & Co.; H.C. Wainwright & Co. |
$40 |
$201.82 |
Synthetic Biologics Inc. (Rockville, Md.; NYSE MKT:SYN)26 |
4/20/15 |
7/17/15 |
15.3S |
$3 |
88.50 |
William Blair (co-lead); RBC Capital Markets (co-lead); BTIG |
$46 |
$265.5 |
Theratech-nologies Inc. (Montreal; TSX:TH)27 |
7/27/15 |
7/31/15 |
4.6U |
C$2.4 |
N/A |
N/A |
$8.4 |
N/A |
Tonix Pharmaceuticals Holding Corp. (New York; TNXP)28 |
8/1/14 |
7/15/15 |
2.67S |
$7.50 |
18.83 |
Roth Capital Partners (co-lead); Oppenheimer & Co. (co-lead); Janney Montgomery Scott |
$20.05 |
$141.23 |
Ultragenyx Pharmaceutical Inc. (Novato, Calif.; RARE)29 |
7/14/15 |
7/17/15 |
2.53S |
$120 |
38.14 |
Morgan Stanley (co-lead); J.P. Morgan (co-lead); Cowen and Co. (co-lead); JMP Securities; Wedbush Pacgrow |
$303.6 |
$4,576.8 |
Zogenix Inc. (San Diego; ZGNX)30 |
1/20/15 |
7/30/15 |
4.75S |
$18 |
23.92 |
Leerink Partners (co-lead); Stifel (co-lead); Oppenheimer & Co.; Brean Capital |
$85.5 |
$430.56 |
|
Number of follow-on offerings in July: 26 Average value of July follow-ons: $99.94M Number of follow-on offerings in 2015: 161 Total raised in follow-ons in 2015: $16,374.47M Average value of follow-ons in 2015: $101.7M | ||||||||
Notes
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
@ This column reflects the shares outstanding following the offering, when disclosed.
% Market capitalization is calculated based on the offering price.
Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics.
1 Chiasma's overallotment option: 954,750 shares.
2 Includes Nantkwest's overallotment option: 1.24M shares. It also is selling 680,000 shares in a separate private placement to an affiliate of Celgene Corp.
3 Includes Neos' overallotment option: 720,000 shares.
4 Includes Pronai's overallotment option: 1.215M shares.
5 Vtv Therapeutics' overallotment option: 1.17M common shares.
6 Amag's overallotment option: 472,500 shares.
7 Includes Anthera's overallotment option: 500,000 shares.
8 Includes Atara's overallotment option: 519,230 shares.
9 Cara's overallotment option: 564,516 shares.
10 Clovis' overallotment option: 528,846 shares.
11 Cymabay's overallotment option: 1.068M shares.
12 Includes Cytrx's overallotment option: 1.3M shares.
13 Includes DBV's overallotment option: 1.08M ADSs. Each ADS represents one-half of one ordinary share.
14 Discovery priced the offering of 16.3M series A units and 42M series B units. Overallotment option: 8.75M units. Proceeds include $5M in noncash consideration from affiliates of Deerfield Management Co. LP.
15 Includes Dynavax's overallotment option: 681,818 shares of common stock.
16 Includes Egalet's overallotment option: 1M shares.
17 Exelixis' overallotment option: 3.75M shares of common stock.
18 Eyegate's overallotment option: 176,470 shares and warrants to purchase up to 176,470 shares.
19 Fibrocell's overallotment option: 387,930 shares.
20 Genocea's overallotment option: 577,500 shares.
21 Macrogenics' overallotment option: 528,750 shares.
22 Nephrogenex's overallotment option: 225,000 shares of common stock and/or 225,000 additional warrants.
23 Includes Neuroderm's overallotment option: 590,178 shares.
24 Includes Radius' overallotment option: 608,108 shares.
25 Redhill's overallotment option: 369,300 ADSs. The 2.462ADSs represent 24,620,000 ordinary shares, or 10 shares each.
26 Includes Synthetic Biologics' overallotment option: 2M shares.
27 Each Theratechnologies unit will consist of one common share and one-half of a common share purchase warrant. Includes overallotment option: 600,000 units. Company raised C$11.04M (US$8.4M).
28 Includes Tonix's overallotment option: 348,750 shares.
29 Includes Ultragenyx's overallotment option: 330,000 shares.
30 Zogenix's overallotment option: 712,500 shares.